Pay in 4 interest-free payments of $5.20 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
If any apply, the medication should not be prescribed: Personal or family history of medullary thyroid carcinoma (MTC) Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Known serious hypersensitivity to the active medication or to a related incretin-receptor agonist Clinical precautions that prompt careful screening These are not absolute contraindications on the FDA label, but they meaningfully change the risk-benefit conversation
Smaller changes do not necessarily mean the medication is not working
Clinical trials show oral semaglutide produces 10-15% weight loss, compared to 15-22% for the same dose injected, a meaningful difference over a year of treatment
The retatrutide versus semaglutide comparison becomes even more dramatic when you consider these results came from a 48-week trial, not the 68-week trials used for semaglutide data
